Robert W. Baird Increases Neurogene (NASDAQ:NGNE) Price Target to $72.00

Neurogene (NASDAQ:NGNE) had its price objective hoisted by Robert W. Baird from $54.00 to $72.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 0.66% from the company’s current price.

Separately, HC Wainwright reduced their target price on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $55.00.

Neurogene Trading Up 4.9 %

NASDAQ:NGNE opened at $71.53 on Tuesday. The business’s 50-day simple moving average is $46.77 and its 200-day simple moving average is $40.05. Neurogene has a fifty-two week low of $12.49 and a fifty-two week high of $74.49.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.07). The business had revenue of $0.93 million for the quarter. As a group, sell-side analysts anticipate that Neurogene will post -4.44 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NGNE. Jennison Associates LLC bought a new stake in shares of Neurogene during the 3rd quarter worth approximately $3,300,000. SG Americas Securities LLC bought a new stake in Neurogene during the third quarter worth $150,000. Driehaus Capital Management LLC lifted its stake in Neurogene by 123.8% in the second quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after acquiring an additional 56,533 shares during the last quarter. Marshall Wace LLP lifted its stake in Neurogene by 37.2% in the 2nd quarter. Marshall Wace LLP now owns 41,447 shares of the company’s stock valued at $1,508,000 after purchasing an additional 11,229 shares during the last quarter. Finally, Integral Health Asset Management LLC acquired a new stake in shares of Neurogene in the second quarter valued at approximately $2,547,000. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.